Circulating miR-142-3p levels in patients with systemic sclerosis.

Area of Science:

• Biochemistry
• Molecular Biology
• Immunology

Background:

• Serum microRNAs (miRNAs) are emerging biomarkers for disease diagnosis and prognosis.
• Investigating serum miRNA in systemic sclerosis (SSc) is crucial due to its potential diagnostic value.
• Previous studies have not explored serum miRNA levels in SSc patients.

Purpose of the Study:

• To determine if serum levels of Homo sapiens miR-142 stem-loop (hsa-miR-142-3p) can serve as a specific disease marker for SSc.
• To assess the role of hsa-miR-142-3p, a regulator of integrin αV expression, in SSc pathogenesis.
• To explore the diagnostic potential of hsa-miR-142-3p in distinguishing SSc from related conditions.

Main Methods:

• Quantitative real-time PCR was used to measure hsa-miR-142-3p levels in serum samples.
• Serum was collected from 61 SSc patients and 20 healthy controls.
• Disease controls included patients with systemic lupus erythematosus (SLE), dermatomyositis (DM), and scleroderma spectrum disorder (SSD).

Main Results:

• Serum hsa-miR-142-3p levels were significantly higher in SSc patients compared to healthy controls and patients with SSD, SLE, or DM.
• Elevated hsa-miR-142-3p levels showed a tendency to correlate with a short sublingual frenulum.
• These findings indicate a specific elevation of hsa-miR-142-3p in SSc patients.

Conclusions:

• Serum hsa-miR-142-3p levels may be specifically elevated in SSc patients.
• hsa-miR-142-3p shows potential as a diagnostic marker for SSc.
• This miRNA could aid in differentiating SSc from scleroderma spectrum disorder (SSD).